Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 166

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

The journey of remdesivir: from Ebola to COVID-19

Open access
Pardo, Joe, Shukla, Ashutosh M, Chamarthi, Gajapathiraju, Gupte, Asmita · 2020 · Drugs in Context

Abstract

Countries around the world are currently fighting the coronavirus disease 2019 (COVID-19) pandemic, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).SARS-CoV-2 is a betacoronavirus, belonging to the same genus as severe acute respiratory syndrome (SARS)-CoV and Middle East respiratory syndrome (MERS)-CoV.Currently, there are no proven antiviral therapies for COVID-19.Numerous clinical trials have been initiated to identify an effective treatment.One leading candidate is remdesivir (GS-5734), a broad-spectrum antiviral that was initially developed for the treatment of Ebola virus (EBOV).Although remdesivir performed well in preclinical studies, it did not meet efficacy endpoints in a randomized trial conducted during an Ebola outbreak.Remdesivir holds promise for treating COVID-19 based on in vitro activity against SARS-CoV-2, uncontrolled clinical reports, and limited data from randomized trials.Overall, current data are insufficient to judge the efficacy of remdesivir for COVID-19, and the results of additional randomized studies are eagerly anticipated.In this narrative review, we provide an overview of Ebola and coronavirus outbreaks.We then summarize preclinical and clinical studies of remdesivir for Ebola and COVID-19.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7573/dic.2020-4-14

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 166

Metadata

Authors
Pardo, J., Shukla, A. M., Chamarthi, G., & Gupte, A.
Venue
Drugs in Context
Publisher
BioExcel
Published
2020-05-22
Volume
9
Pages
1-9
ISSN
1740-4398 (ISSN-L)
OpenAlex
W3027858755
Cited by
166
References
7
FWCI
4.10
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The journey of remdesivir: from Ebola to COVID-19. https://app.cochat.ai/papers/10.7573/dic.2020-4-14
The paper
Pardo, J., Shukla, A. M., Chamarthi, G., & Gupte, A. (2020). The journey of remdesivir: from Ebola to COVID-19. Drugs in Context. https://doi.org/10.7573/dic.2020-4-14

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.